| Literature DB >> 30979708 |
Chuantao Fang1, Jian Li1, Sixian Qi1, Yubin Lei1, Yan Zeng1, Pengcheng Yu2,3, Zhaolan Hu4, Yufeng Zhou1, Yulong Wang2,3, Ruping Dai4, Jin Li1, Shenglin Huang5, Pinglong Xu6, Kang Chen7,8,9, Chen Ding10, Fa-Xing Yu11.
Abstract
Type I interferon (IFN)-induced Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling drives the expression of IFN-stimulated genes (ISGs) to mediate antiviral response. The strength and duration of JAK-STAT signaling are tightly regulated to ensure effective antiviral defense while avoiding pathological inflammation and autoimmunity. Here, we report that cTAZ, an isoform of the Hippo pathway effector TAZ, is transcribed by an alternative promoter. Although majority of C-terminal sequences of TAZ is retained, cTAZ is not regulated by the Hippo signaling and does not mediate its growth-inhibitory functions. Instead, cTAZ negatively regulates JAK-STAT signaling by inhibiting STAT1/2 nuclear localization and ISG expression, and its expression is induced by type I IFN Thus, cTAZ functions as a modulator of JAK-STAT signaling and may play a role in fine-tuning cellular antiviral response.Entities:
Keywords: Hippo pathway; JAK‐STAT pathway; alternative transcript; viral infection
Mesh:
Substances:
Year: 2019 PMID: 30979708 PMCID: PMC6549033 DOI: 10.15252/embr.201847227
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807